suMMARY The presence of phytanic acid in tissues and plasma has been considered diagnostic of heredopathia atactica polyneuritiformis (Refsum's disease), but recently slightly raised plasma phytanic acid levels have been reported in other conditions. Forty two normal people were found to have a phytanic acid level of 0-33Mmol/l. Fourteen patients with heredopathia atactica polyneuritiformis had a plasma phytanic acid level before treatment of 992-6400 Mmol/l. Five patients with retinitis pigmentosa but not heredopathia atactica polyneuritiformis had plasma levels of 38-192 pmol/l. It was concluded that some patients with retinitis pigmentosa without heredopathia atactica polyneuritiformis but a raised plasma phytanic acid may represent a group ofpatients with a disease or diseases as yet uncharacterised apart from the retinal condition.
Phytanic acid (3, 7, 11, 15 tetramethylhexadecanoic acid) is a normal constituent of food and is found particularly in the fat ofruminant animals and in dairy products.' Unlike other naturally occurring fatty acids, phytanic acid cannot be metabolised by betaoxidation because the methyl side chains block the enzymatic action; an initial alpha-oxidation is necessary for its catabolism.' As a result of a specific defect in alpha-oxidation in patients with heredopathia atactica polyneuritiformis (HAP) (Refsum's disease)2 phytanic acid accumulates in large amounts in their tissues and plasma.3 The disease is characterised by retinitis pigmentosa, ataxia and polyneuropathy4 and in addition there may be anosmia, sensorineural hearing loss, ichthyosis and cardiac abnormalities. At the time of diagnosis patients with HAP usually have plasma phytanic acid levels above 800 umol/15 while normal people have been considered to have undetectable levels.
Recently abnormalities in the fatty acids including moderately raised phytanic acid levels have been reported in several childhood conditions6 including Zellweger's syndrome, adrenoleukodystrophy, infantile Refsum's syndrome and pipecolic acidaemia.7'2 A plasma phytanic acid level as high as 320 pmol/l was found in one case of adrenoleukodystrophy. 6 The plasma levels of other fatty acids are also abnormal in these conditions. In some of these children there is a more general abnormality in the number of peroxisomes in the skin fibroblasts and therefore this group of conditions, in none of which is the biochemical abnormality confined to a defect of phytanic acid metabolism, has been termed the peroxisomal disorders. '3 The significance of plasma phytanic acid levels in adults is uncertain. Although very high levels of plasma phytanic acid are diagnostic of HAP,3"4 the interpretation of lower levels is more difficult. The level of phytanic acid in the plasma of patients with HAP varies considerably6 as it rises when the disease worsens and may fall to very low levels with treatment.5"5 Low levels of phytanic acid have been detected in relatives of patients with HAP.
Methods
Forty two hospital inpatients were studied: 37 preoperative orthopaedic patients and five general medicine patients.
Their consent was obtained and venous blood taken on two occasions; first in the afternoon as a random non-fasting sample and the second in the morning after at least an 8 The results given are the means of several readings. The significance ofplasma phytanic acid levels in adults Discussion
The presence of trace amounts of phytanic acid in a normal population has been reported previously'4"8 but the normal range has never been defined. Avigan" measured the phytanic acid in a pooled sample of sera from 200 non-fasting healthy male blood donors and obtained a value of 6-4 umol/l for phytanic acid, a figure which is close to the average found in this study.
In the three individual samples measured the level was 1-3 to 6-4 Mmol/1.'4 Kremer" reported the phytanic acid levels to vary between 0-2 and 0-6% of total lipids which is a test not directly comparable, as the total lipid levels were not stated. Two other workers have separately attempted to measure phytanic acid levels in controls. Try'9 found the phytanic acid not raised in the plasma of 73 patients who had retinitis pigmentosa or a neurological disorder, but the limit ofdetection of the assay was only 64 umol/l and Poulos2' found all 50 of his controls to have less than 16 pmol/l which was the limit of detection of his assay.
The method of assay used in the present study is similar to previous methods, but a table 2 ). However none of these five patients had a plasma level sufficiently elevated to be comparable with the initial plasma phytanic acid levels of the 14 patients with HAP. These five patients may be suffering from a syndrome independent of HAP, which is associated with a mild rise in the phytanic acid level in the blood. Using the techniques described in this paper and having defined a normal limit for the plasma phytanic acid it should now be possible to distinguish a group of adults who are not relatives of patients with HAP and therefore possible carriers of a gene for HAP but who have unelucidated conditions which are not infantile peroxisomal disorders but which cause slight elevation of phytanic acid levels. In summary, for patients with recognised syndromes the plasma phytanic acids which may occur are given in table 2. The five patients in table I would not conform to one of the recognised groups and could represent a separate entity.
